Literature DB >> 17000905

Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice.

Paola Secchiero1, Riccardo Candido, Federica Corallini, Serena Zacchigna, Barbara Toffoli, Erika Rimondi, Bruno Fabris, Mauro Giacca, Giorgio Zauli.   

Abstract

BACKGROUND: Although in vitro studies have suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) might be involved in vascular biology, its potential role in the pathogenesis and/or treatment of atherosclerosis has not been investigated. METHODS AND
RESULTS: Both recombinant human TRAIL and an adeno-associated virus vector expressing human TRAIL were used to deliver TRAIL in apolipoprotein E (apoE)-null mice in which diabetes mellitus was induced by destruction of islet cells with streptozotocin. Diabetes in apoE-null mice was associated with a significant increase in atherosclerotic plaque area and complexity in the aorta as assessed by a marked increase in interstitial collagen, cellular proliferation, and macrophage infiltration and a focal loss of endothelial coverage. Repeated intraperitoneal injections of recombinant human TRAIL and a single intravenous injection of adeno-associated virus-human TRAIL significantly attenuated the development of atherosclerotic plaques in apoE-null animals. TRAIL also markedly affected the cellular composition of plaque lesions by inducing apoptosis of infiltrating macrophages and increasing the vascular smooth muscle cell content. Moreover, TRAIL promoted the in vitro migration of cultured human aortic vascular smooth muscle cells but not of monocytes or macrophages. Conversely, TRAIL selectively induced apoptosis of human cultured macrophages but not of vascular smooth muscle cells.
CONCLUSIONS: Overall, data from the present study indicate that atherosclerosis in diabetic apoE-null mice is ameliorated by systemic TRAIL administration and that adeno-associated virus-mediated TRAIL gene delivery might represent an innovative method for the therapy of diabetic vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17000905     DOI: 10.1161/CIRCULATIONAHA.106.643841

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  58 in total

1.  The negative prognostic value of TRAIL overexpression in oral squamous cell carcinomas does not preclude the potential therapeutic use of recombinant TRAIL.

Authors:  Francesco Carinci; Lorenzo Monasta; Corrado Rubini; Daniela Stramazzotti; Annalisa Palmieri; Elisabetta Melloni; Alex Knowles; Luca Ronfani; Giorgio Zauli; Paola Secchiero
Journal:  Invest New Drugs       Date:  2010-11-18       Impact factor: 3.850

2.  TRAIL shows potential cardioprotective activity.

Authors:  Barbara Toffoli; Stella Bernardi; Riccardo Candido; Serena Zacchigna; Bruno Fabris; Paola Secchiero
Journal:  Invest New Drugs       Date:  2011-01-04       Impact factor: 3.850

Review 3.  Therapeutic strategies to deplete macrophages in atherosclerotic plaques.

Authors:  Inge De Meyer; Wim Martinet; Guido R Y De Meyer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

4.  Decreased serum TRAIL is associated with increased mortality in smokers with comorbid emphysema and coronary artery disease.

Authors:  Oluremi Ajala; Yingze Zhang; Aman Gupta; Jessica Bon; Frank Sciurba; Divay Chandra
Journal:  Respir Med       Date:  2018-10-19       Impact factor: 3.415

5.  Soluble TNF-related apoptosis induced ligand (sTRAIL) is augmented by Post-Conditioning and correlates to infarct size and left ventricle dysfunction in STEMI patients: a substudy from a randomized clinical trial.

Authors:  André Luz; Mário Santos; Rui Magalhães; José Carlos Oliveira; Ana Pacheco; João Silveira; Sofia Cabral; Severo Torres; Adelino F Leite-Moreira; Henrique Carvalho
Journal:  Heart Vessels       Date:  2016-05-26       Impact factor: 2.037

6.  Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adults.

Authors:  Stefano Volpato; Luigi Ferrucci; Paola Secchiero; Federica Corallini; Giovanni Zuliani; Renato Fellin; Jack M Guralnik; Stefania Bandinelli; Giorgio Zauli
Journal:  Atherosclerosis       Date:  2010-11-11       Impact factor: 5.162

Review 7.  Transcriptional regulation of tumour necrosis factor-related apoptosis-inducing ligand.

Authors:  Nor Saadah M Azahri; Mary M Kavurma
Journal:  Cell Mol Life Sci       Date:  2013-01-18       Impact factor: 9.261

8.  Functional screening identifies miRNAs inducing cardiac regeneration.

Authors:  Ana Eulalio; Miguel Mano; Matteo Dal Ferro; Lorena Zentilin; Gianfranco Sinagra; Serena Zacchigna; Mauro Giacca
Journal:  Nature       Date:  2012-12-05       Impact factor: 49.962

Review 9.  The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression.

Authors:  Ira Tabas; Alan Tall; Domenico Accili
Journal:  Circ Res       Date:  2010-01-08       Impact factor: 17.367

10.  Maternal plasma soluble TRAIL is decreased in preeclampsia.

Authors:  Piya Chaemsaithong; Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Tamara Stampalija; Nandor Gabor Than; Zhong Dong; Jezid Miranda; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2013-08-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.